nach oben

Erschienen in:

01.04.2018 | Original Article

Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients

verfasst von: Humaira Naeemi, Rabia Aslam, Syed Mohsin Raza, Muhammad Aiman Shahzad, Shagufta Naz, Sobia Manzoor, Saba Khaliq

Erschienen in: Archives of Virology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

There are over 10 million hepatitis C virus (HCV)-infected patients in Pakistan. For these patients, a combination of interferon with ribavirin is the most economical and easily available treatment. Single-nucleotide polymorphisms in interleukin genes have been reported to be associated with the pathogenesis and clearance of HCV, and sustained virologic response (SVR). An interleukin 28B (IL28B) gene polymorphism has been shown to modify treatment outcomes, but the effects of interleukin 10 (IL10) polymorphisms have not been previously assessed in the Pakistani population. The present study was conducted with 302 subjects categorized into two groups: 100 healthy volunteers (Group I) and 202 patients with chronic HCV (Group II). Patients within Group II were further divided into two subgroups according to therapeutic response: SVR (responders = 132) and NR (non-responders/relapsers = 70). IL28B (rs8099917, rs12979860) and IL10 (rs1800872, rs1800871, rs1800896) gene polymorphisms were studied in all subjects. A significant difference in the distribution of IL28B rs12979860C/T genotypes between the two groups (p<0.05) was observed, while of the three IL10 polymorphisms, a significant difference was only shown for rs1800896 A/G. Haplotype analysis (IL28B and IL10) showed a significant association of TTGTC and TTGTA when comparing the groups. There was a strong association of the favorable alleles rs8099917T and rs12979860C in the SVR group as compared with the NR group (p<0.05), and rs1800896 also showed an association with the SVR group as compared to the NR group (p<0.004). Haplotype analysis showed significant associations when comparing the SVR and NR subgroups, i.e. TCATC (p=0.009), TTGTA (p=0.005), TCATA (p<0.0005), TCACA (p=0.002), GTGCC (p=0.002) and TCGTC (p=0.005). IL28B (rs8099917 and rs12979860) and IL10 (rs1800896) polymorphisms alone, or in combination, are good predictors of therapeutic response in HCV-3a patients.

Nur mit Berechtigung zugänglich

Abdelraheem WM, Hassuna NA, Abuloyoun SM, Abdel Ghany HM, Rizk HA, Abdelwahab SF (2016) Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin. Arch Virol 161:2473–2480CrossRef

Afzal MS, Tahir S, Salman A, Baig TA, Shafi T, Zaidi NU, Qadri I (2011) Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries 5:473–479CrossRef

Afzal MS, Anjum S, Zaidi NU (2013) Effect of functional interleukin-10 polymorphism on pegylated interferon-alpha plus ribavirin therapy response in chronic hepatitis c virus patients infected with 3a genotype in Pakistani population. Hepat Mon 13:e10274CrossRef

Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, Lankarani KB (2010) Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int Off J Int Assoc Study Liver 30:1173–1180CrossRef

Aslam R, Raza SM, Naeemi H, Mubarak B, Afzal N, Khaliq S (2016) SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment. Springerplus 5:1826CrossRef

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML (2015) Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 30:91–97

Bahgat NA, Kamal MM, Abdelaziz AO, Mohye MA, Shousha HI, Ahmed MM, Elbaz TM, Nabil NM (2015) Interferon-gamma and interleukin-10 gene polymorphisms are not predictors of chronic hepatitis C (genotype-4) disease progression. Asian Pac J Cancer Prev APJCP 16:5025–5030CrossRef

Bouzgarrou N, Hassen E, Farhat K, Bahri O, Gabbouj S, Maamouri N, Ben Mami N, Saffar H, Trabelsi A, Triki H, Chouchane L (2009) Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 70:230–236CrossRef

da Silva Conde SR, Soares Monteiro JC, Silva Dos Santos BT, Fonseca Filgueiras NK, de Almeida Lins PA, Bonfim Freitas F, da Silva Graca E, Demachki S, Ferreira de Araujo MT, Ishak R, Rosario Vallinoto AC (2014) SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment. Biomed Res Int 2014:748606CrossRef

10.

da Silva NM, Germano FN, Vidales-Braz BM, Carmo Zanella R, dos Santos DM, Lobato R, de Martinez AM (2015) Polymorphisms of IL-10 gene in patients infected with HCV under antiviral treatment in southern Brazil. Cytokine 73:253–257CrossRef

11.

Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-dweik N, Yakoob R, Pasic F, Almohanadi M, Alejji K, Abdelmola A, Butt M (2013) The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology 444:292–300CrossRef

12.

Dzekova-Vidimliski P, Nikolov IG, Matevska-Geshkovska N, Boyanova Y, Nikolova N, Romanciuc G, Dumitrascu D, Caloska-Ivanova V, Joksimovic N, Antonov K, Mateva L, Rostaing L, Dimovski A, Sikole A (2015) Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci 15:55–59CrossRef

13.

El-Karaksy HM, Sharaf SA, Mandour IA, Mogahed EA, Rady NH, El-Mougy FA (2016) Effect of interleukin-10 gene promoter polymorphisms-1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection. Hum Immunol 77:1248–1253CrossRef

14.

Ezzikouri S, Alaoui R, Rebbani K, Brahim I, Fakhir FZ, Nadir S, Diepolder H, Khakoo SI, Thursz M, Benjelloun S (2013) Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One 8:e54793CrossRef

15.

Goossens N, Negro F (2014) Is genotype 3 of the hepatitis C virus the new villain? Hepatology 59:2403–2412CrossRef

16.

Guo P, Li G, Sun X, Wu D (2016) Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis 45:48–55

17.

Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F (2015) Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol 21:8935–8942CrossRef

18.

Hashmi AH, Ahmad N, Riaz S, Ali L, Siddiqi S, Khan KM, Shakoori AR, Mansoor A (2014) Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection. Genes Immun 15:430–432CrossRef

19.

Hayes CN, Imamura M, Aikata H, Chayama K (2012) Genetics of IL28B and HCV-response to infection and treatment. Nat Rev Gastroenterol Hepatol 9:406–417CrossRef

20.

Helal SF, Gomaa HE, Thabet EH, Younan MA, Helmy NA (2014) Impact of IL-10 (-1082) promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol 7:19–24CrossRef

21.

Idrees M (2008) Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J Virol Methods 150:50–56CrossRef

22.

Imran M, Manzoor S, Ashraf J, Khalid M, Tariq M, Khaliq HM, Azam S (2013) Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J 10:299CrossRef

23.

Imran M, Manzoor S, Azam S, Resham S (2015) Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population. APMIS Acta Pathol Microbiol Immunol Scand 123:342–349CrossRef

24.

Jablonowska E, Piekarska A, Koslinska-Berkan E, Omulecka A, Szymanska B, Wojcik K (2012) Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Acta Biochim Pol 59:333–337CrossRef

25.

Kaczor MP, Seczynska M, Szczeklik W, Sanak M (2015) IL28B polymorphism (rs12979860) associated with clearance of HCV infection in Poland: systematic review of its prevalence in chronic hepatitis C patients and general population frequency. Pharmacol Rep PR 67:260–266CrossRef

26.

Khubaib B, Saleem S, Idrees M, Afzal S, Wasim M (2015) The genotype CC of IL-28B SNP rs12979860 is significantly associated with a sustained virological response in chronic HCV-infected Pakistani patients. J Dig Dis 16:293–298CrossRef

27.

Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M (2012) High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 56:2039–2050CrossRef

28.

Par A, Par G, Tornai I, Szalay F, Varszegi D, Frater E, Papp M, Lengyel G, Feher J, Varga M, Gervain J, Schuller J, Nemes Z, Peterfi Z, Tusnadi A, Hunyady B, Haragh A, Szinku Z, Vincze A, Szereday L, Kisfali P, Melegh B (2014) IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort. BMC Res Notes 7:12CrossRef

29.

Ramos JA, Silva R, Hoffmann L, Ramos AL, Cabello PH, Urmenyi TP, Villella-Nogueira CA, Lewis-Ximenez L, Rondinelli E (2012) Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Res Notes 5:508CrossRef

30.

Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis CCS, Swiss HIVCS (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338–1345 (1345 e1331–1337) CrossRef

31.

Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO (2016) Pretreatment predictors of response to PegIFN-RBV therapy in Egyptian patients with HCV genotype 4. PLoS One 11:e0153895CrossRef

32.

Sepahi S, Pasdar A, Ahadi M, Gerayli S, Rostami S, Meshkat Z (2014) Haplotype analysis of interleukin-10 gene promoter polymorphisms in chronic hepatitis C infection: a case–control study. Viral Immunol 27:398–403CrossRef

33.

Sghaier I, Mouelhi L, Rabia NA, Alsaleh BR, Ghazoueni E, Almawi WY, Loueslati BY (2017) Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine 89:62–67CrossRef

34.

Shaikh N, Waryah AM, Devrajani BR, Rajput MI, Hayat AS, Shaikh S (2015) IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C. J Med Virol 87:814–820CrossRef

35.

Shaker OG, Sadik NA (2012) Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. J Gastroenterol Hepatol 27:1842–1849CrossRef

36.

Shaker OG, Abdel-Rahim MT, Bayoumi ST (2015) Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4. Cell Biochem Biophys 71:617–625CrossRef

37.

Swiatek-Koscielna B, Kaluzna E, Strauss E, Januszkiewicz-Lewandowska D, Bereszynska I, Wysocki J, Rembowska J, Barcinska D, Antosik D, Mozer-Lisewska I, Nowak J (2017) Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: analysis of association with severity of disease and treatment outcome. Hum Immunol 78:192–200CrossRef

38.

Thrift AP, El-Serag HB, Kanwal F (2017) Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 14:122–132CrossRef

39.

Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S (2017) Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res. https://doi.org/10.1111/hepr.12980 CrossRef

40.

Umer M, Iqbal M (2016) Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol 22:1684–1700CrossRef

Titel: Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients
verfasst von: Humaira Naeemi
Rabia Aslam
Syed Mohsin Raza
Muhammad Aiman Shahzad
Shagufta Naz
Sobia Manzoor
Saba Khaliq
Publikationsdatum: 01.04.2018
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 4/2018
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-018-3711-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Correction to: Complete genome sequence of a phage hyperparasite of Candidatus Xenohaliotis californiensis (Rickettsiales) – a pathogen of Haliotis spp (Gasteropoda)

Genetic and biological characterization of three poultry-origin H5N6 avian influenza viruses with all internal genes from genotype S H9N2 viruses

Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens

Comparative evaluation of the Omniplex-HPV and RFMP HPV PapilloTyper for detecting human papillomavirus genotypes in cervical specimens

Mitochondrial bioenergy alterations in avian HD11 macrophages infected with infectious bronchitis virus

A novel passerivirus (family Picornaviridae) in an outbreak of enteritis with high mortality in estrildid finches (Uraeginthus sp.)

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin